sim0417
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Jul 21, 2022 (NCT05475834)
Timeline
Indications
Mechanism of action
- Replicase polyprotein 1aINHIBITOR
Replicase polyprotein 1a inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05826249 | Phase 1 | Apr 7, 2023 | Shandong Province Qianfoshan Hospital, Simcere Pharmaceutical Co., Ltd |
| NCT05731804 | Phase 1 | Mar 1, 2023 | Shandong first medical University, Simcere Pharmaceutical Co., Ltd |
| NCT05665647 | Phase 1 | Dec 29, 2022 | Shandong first medical University, Simcere Pharmaceutical Co., Ltd |
| NCT05506176 | Phase 2/Phase 3 (Phase 3) | Aug 31, 2022 | Peking University, Simcere Pharmaceutical Co., Ltd |
| NCT05475834 | Phase 1 | Jul 21, 2022 | Shandong first medical University, Simcere Pharmaceutical Co., Ltd |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Simcere Pharmaceutical Co., Ltd | For profit | 5 | 5 | 2 | 2022 |
| Shandong first medical University | Academic/Hospital | 3 | 0 | 1 | 2022 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Shandong Province Qianfoshan Hospital | Academic/Hospital | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1